Shares in Ultragenyx and Mereo BioPharma have plunged after their drug for osteogenesis imperfecta (OI) or brittle bone ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Newland, CEO of ANGLE, about why live cell liquid ...

The NHS has an extraordinary opportunity in 2026. Unified data, decision intelligence, and strong workforce capability can ...

Judge Lance Walker sided with the American Hospital Association (AHA) and other plaintiffs in the lawsuit, brought in a Maine ...

In 2026, we will see widespread adoption of AI tools that automate time-consuming administrative tasks: drafting clinical ...

Long-serving Roche chief executive Severin Schwan is stepping down, to be replaced next March by Thomas Schinecker, currently head of diagnostics at the Swiss group. Schwan (pictured above) has been ...

Eli Lilly has said it will raise the UK list price of its diabetes and obesity therapy Mounjaro for people who buy the drug out of their own pocket, to bring it into parity with other European markets ...

It's all change at Alphabet's life sciences business Verily, with a $1 billion funding round and a shake-up of its senior leadership, including a new chief executive and executive chairman, who will ...

Ireland is attracting major investment from the largest pharma companies in the world. Ben Hargreaves finds out how the country has become one of the most significant locations in Europe for ...

Brand new UK startup RQ Biotechnology has been thrust into the spotlight after signing a $157 million licensing deal with AstraZeneca for monoclonal antibodies intended to protect vulnerable and ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations. The Danish ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by the FDA, and the partners have now withdrawn a filing intended to get the ...